Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.
2.

Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.

Dudnik E, Siegal T, Zach L, Allen AM, Flex D, Yust-Katz S, Limon D, Hirsch FR, Peled N.

J Clin Neurosci. 2016 Apr;26:46-9. doi: 10.1016/j.jocn.2015.05.068. Epub 2015 Dec 8.

PMID:
26677785
3.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.

Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.

PMID:
25153538
4.

Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?

Chun SG, Choe KS, Iyengar P, Yordy JS, Timmerman RD.

Cancer Biol Ther. 2012 Dec;13(14):1376-83. doi: 10.4161/cbt.22255. Epub 2012 Sep 17.

5.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crinò L.

J Clin Oncol. 2015 Jun 10;33(17):1881-8. doi: 10.1200/JCO.2014.59.0539. Epub 2015 Jan 26.

6.

Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer.

Kinoshita Y, Koga Y, Sakamoto A, Hidaka K.

BMJ Case Rep. 2013 Sep 10;2013. pii: bcr-2013-200867. doi: 10.1136/bcr-2013-200867.

7.

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR.

J Thorac Oncol. 2012 Dec;7(12):1807-14. doi: 10.1097/JTO.0b013e3182745948.

8.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR.

Lancet Oncol. 2011 Oct;12(11):1004-12. doi: 10.1016/S1470-2045(11)70232-7. Epub 2011 Sep 18.

9.

Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.

Guérin A, Sasane M, Wakelee H, Zhang J, Culver K, Dea K, Nitulescu R, Galebach P, Macalalad AR.

Curr Med Res Opin. 2015 Aug;31(8):1587-97. doi: 10.1185/03007995.2015.1057115. Epub 2015 Jun 29.

PMID:
26029864
10.

FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.

Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, Keegan P, Pazdur R.

Oncologist. 2014 Oct;19(10):e5-11. doi: 10.1634/theoncologist.2014-0241. Epub 2014 Aug 28.

11.

EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.

Wang Y, Zhang J, Gao G, Li X, Zhao C, He Y, Su C, Zhang S, Chen X, Zhang J, Li W, Li B, Zhao J, Hou L, Wu C, Ren S, Zhou C, Zhang J.

J Thorac Oncol. 2015 Nov;10(11):1546-52. doi: 10.1097/JTO.0000000000000668.

12.

Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.

Peled N, Zach L, Liran O, Ilouze M, Bunn PA Jr, Hirsch FR.

J Thorac Oncol. 2013 Dec;8(12):e112-3. doi: 10.1097/JTO.0000000000000038. No abstract available.

13.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.

N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588.

14.

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.

O'Bryant CL, Wenger SD, Kim M, Thompson LA.

Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5. Review.

PMID:
23386065
15.

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW.

J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/JCO.2015.63.9443. Epub 2015 Nov 23.

PMID:
26598747
16.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ.

N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27.

17.

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

Ou SH, Jänne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, Crinò L, Selaru P, Cohen DP, Clark JW, Riely GJ.

Ann Oncol. 2014 Feb;25(2):415-22. doi: 10.1093/annonc/mdt572.

PMID:
24478318
18.

ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?

Toyokawa G, Seto T.

Clin Lung Cancer. 2014 Sep;15(5):313-9. doi: 10.1016/j.cllc.2014.05.001. Epub 2014 Jun 2. Review.

PMID:
24984564
19.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA.

N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1. Erratum in: N Engl J Med. 2015 Oct 15;373(16):1582.

20.

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.

Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN.

J Clin Oncol. 2016 Jan 10;34(2):123-9. doi: 10.1200/JCO.2015.62.0138. Epub 2015 Oct 5.

Supplemental Content

Support Center